(Q42199714)

18 October 2017

Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food (English)

1 reference

18 October 2017

1 reference

1 reference

1 reference

1

1 reference

18 October 2017

Vanitha Sekar

2

1 reference

18 October 2017

Ludo Lavreys

3

1 reference

18 October 2017

Els De Paepe

4

1 reference

18 October 2017

Tanja Stevens

5

1 reference

18 October 2017

Marc Vanstockem

6

1 reference

18 October 2017

Tony Vangeneugden

7

1 reference

18 October 2017

Richard M W Hoetelmans

8

1 reference

18 October 2017

10 February 2014

1 reference

Clinical pharmacology in drug development

18 October 2017

1 reference

18 October 2017

3

1 reference

18 October 2017

5

1 reference

18 October 2017

346-352

1 reference

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

18 October 2017

1 reference

Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence?

21 January 2018

1 reference

Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

21 January 2018

1 reference

Association of antiretroviral therapy adherence and health care costs

21 January 2018

1 reference

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time

21 January 2018

1 reference

Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report

21 January 2018

1 reference

Biopharmaceutic planning in pediatric drug development

21 January 2018

1 reference

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

21 January 2018

1 reference

21 January 2018

1 reference

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers

21 January 2018

1 reference

Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone

21 January 2018

1 reference

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients

21 January 2018

1 reference

Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults

21 January 2018

1 reference

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

21 January 2018

1 reference

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

21 January 2018

1 reference

Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects

21 January 2018

1 reference

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

21 January 2018

1 reference

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals

21 January 2018

1 reference

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CPDD.88

1 reference

18 October 2017

1 reference